iRhom2 regulates ectodomain shedding and surface expression of the major histocompatibility complex (MHC) class I.

ADAM17 MHC class I molecules Macrophages Secretome iRhom2

Journal

Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402

Informations de publication

Date de publication:
04 Apr 2024
Historique:
received: 29 11 2023
accepted: 04 03 2024
revised: 22 02 2024
medline: 4 4 2024
pubmed: 4 4 2024
entrez: 3 4 2024
Statut: epublish

Résumé

Proteolytic release of transmembrane proteins from the cell surface, the so called ectodomain shedding, is a key process in inflammation. Inactive rhomboid 2 (iRhom2) plays a crucial role in this context, in that it guides maturation and function of the sheddase ADAM17 (a disintegrin and metalloproteinase 17) in immune cells, and, ultimately, its ability to release inflammatory mediators such as tumor necrosis factor α (TNFα). Yet, the macrophage sheddome of iRhom2/ADAM17, which is the collection of substrates that are released by the proteolytic complex, is only partly known. In this study, we applied high-resolution proteomics to murine and human iRhom2-deficient macrophages for a systematic identification of substrates, and therefore functions, of the iRhom2/ADAM17 proteolytic complex. We found that iRhom2 loss suppressed the release of a group of transmembrane proteins, including known (e.g. CSF1R) and putative novel ADAM17 substrates. In the latter group, shedding of major histocompatibility complex class I molecules (MHC-I) was consistently reduced in both murine and human macrophages when iRhom2 was ablated. Intriguingly, it emerged that in addition to its shedding, iRhom2 could also control surface expression of MHC-I by an undefined mechanism. We have demonstrated the biological significance of this process by using an in vitro model of CD8

Identifiants

pubmed: 38570362
doi: 10.1007/s00018-024-05201-7
pii: 10.1007/s00018-024-05201-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

163

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM134907
Pays : United States

Informations de copyright

© 2024. The Author(s).

Références

Black RA et al (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729–733. https://doi.org/10.1038/385729a0
doi: 10.1038/385729a0 pubmed: 9034190
Calligaris M et al (2021) Strategies to target ADAM17 in disease: from its discovery to the iRhom revolution. Molecules 26:944. https://doi.org/10.3390/molecules26040944
doi: 10.3390/molecules26040944 pubmed: 33579029 pmcid: 7916773
Moss ML et al (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385:733–736. https://doi.org/10.1038/385733a0
doi: 10.1038/385733a0 pubmed: 9034191
Peschon JJ et al (1998) An essential role for ectodomain shedding in mammalian development. Science 282:1281–1284. https://doi.org/10.1126/science.282.5392.1281
doi: 10.1126/science.282.5392.1281 pubmed: 9812885
Zunke F, Rose-John S (2017) The shedding protease ADAM17: physiology and pathophysiology. Biochim Biophys Acta Mol Cell Res 1864:2059–2070. https://doi.org/10.1016/j.bbamcr.2017.07.001
doi: 10.1016/j.bbamcr.2017.07.001 pubmed: 28705384
Dulloo I, Muliyil S, Freeman M (2019) The molecular, cellular and pathophysiological roles of iRhom pseudoproteases. Open Biol 9:190003. https://doi.org/10.1098/rsob.190003
doi: 10.1098/rsob.190003 pubmed: 30890028 pmcid: 6451368
Christova Y, Adrain C, Bambrough P, Ibrahim A, Freeman M (2013) Mammalian iRhoms have distinct physiological functions including an essential role in TACE regulation. EMBO Rep 14:884–890. https://doi.org/10.1038/embor.2013.128
doi: 10.1038/embor.2013.128 pubmed: 23969955 pmcid: 3807218
Li X et al (2015) iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling. Proc Natl Acad Sci U S A 112:6080–6085. https://doi.org/10.1073/pnas.1505649112
doi: 10.1073/pnas.1505649112 pubmed: 25918388 pmcid: 4434755
McIlwain DR et al (2012) iRhom2 regulation of TACE controls TNF-mediated protection against listeria and responses to LPS. Science 335:229–232. https://doi.org/10.1126/science.1214448
doi: 10.1126/science.1214448 pubmed: 22246778 pmcid: 4250273
Adrain C, Zettl M, Christova Y, Taylor N, Freeman M (2012) Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science 335:225–228. https://doi.org/10.1126/science.1214400
doi: 10.1126/science.1214400 pubmed: 22246777 pmcid: 3272371
Giese AA et al (2021) Inflammatory activation of surface molecule shedding by upregulation of the pseudoprotease iRhom2 in colon epithelial cells. Sci Rep 11:24230. https://doi.org/10.1038/s41598-021-03522-2
doi: 10.1038/s41598-021-03522-2 pubmed: 34930929 pmcid: 8688420
Issuree PD et al (2013) iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. J Clin Invest 123:928–932. https://doi.org/10.1172/JCI66168
doi: 10.1172/JCI66168 pubmed: 23348744 pmcid: 3561822
Zhao Y et al (2022) Identification of molecular determinants in iRhoms1 and 2 that contribute to the substrate selectivity of stimulated ADAM17. Int J Mol Sci 23:12796. https://doi.org/10.3390/ijms232112796
doi: 10.3390/ijms232112796 pubmed: 36361585 pmcid: 9654401
Maretzky T et al (2013) iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding. Proc Natl Acad Sci U S A 110:11433–11438. https://doi.org/10.1073/pnas.1302553110
doi: 10.1073/pnas.1302553110 pubmed: 23801765 pmcid: 3710827
Luo WW et al (2016) iRhom2 is essential for innate immunity to DNA viruses by mediating trafficking and stability of the adaptor STING. Nat Immunol 17:1057–1066. https://doi.org/10.1038/ni.3510
doi: 10.1038/ni.3510 pubmed: 27428826
Luo WW et al (2017) iRhom2 is essential for innate immunity to RNA virus by antagonizing ER- and mitochondria-associated degradation of VISA. PLoS Pathog 13:e1006693. https://doi.org/10.1371/journal.ppat.1006693
doi: 10.1371/journal.ppat.1006693 pubmed: 29155878 pmcid: 5722342
Meissner F, Scheltema RA, Mollenkopf HJ, Mann M (2013) Direct proteomic quantification of the secretome of activated immune cells. Science 340:475–478. https://doi.org/10.1126/science.1232578
doi: 10.1126/science.1232578 pubmed: 23620052
Khanolkar A et al (2003) CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells. J Immunol 170:3187–3194. https://doi.org/10.4049/jimmunol.170.6.3187
doi: 10.4049/jimmunol.170.6.3187 pubmed: 12626577
Weiss M, Blazek K, Byrne AJ, Perocheau DP, Udalova IA (2013) IRF5 is a specific marker of inflammatory macrophages in vivo. Mediators Inflamm 2013:245804. https://doi.org/10.1155/2013/245804
doi: 10.1155/2013/245804 pubmed: 24453413 pmcid: 3885211
Wisniewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6:359–362. https://doi.org/10.1038/nmeth.1322
doi: 10.1038/nmeth.1322 pubmed: 19377485
Rappsilber J, Ishihama Y, Mann M (2003) Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem 75:663–670
doi: 10.1021/ac026117i pubmed: 12585499
Ivankov DN et al (2013) QARIP: a web server for quantitative proteomic analysis of regulated intramembrane proteolysis. Nucleic Acids Res 41:W459-464. https://doi.org/10.1093/nar/gkt436
doi: 10.1093/nar/gkt436 pubmed: 23729472 pmcid: 3692105
Tarique AA et al (2015) Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. Am J Respir Cell Mol Biol 53:676–688. https://doi.org/10.1165/rcmb.2015-0012OC
doi: 10.1165/rcmb.2015-0012OC pubmed: 25870903
Schwende H, Fitzke E, Ambs P, Dieter P (1996) Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D3. J Leukoc Biol 59:555–561
doi: 10.1002/jlb.59.4.555 pubmed: 8613704
Nuti E et al (2013) Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models. J Med Chem 56:8089–8103. https://doi.org/10.1021/jm4011753
doi: 10.1021/jm4011753 pubmed: 24044434
Weskamp G et al (2020) ADAM17 stabilizes its interacting partner inactive rhomboid 2 (iRhom2) but not inactive rhomboid 1 (iRhom1). J Biol Chem 295:4350–4358. https://doi.org/10.1074/jbc.RA119.011136
doi: 10.1074/jbc.RA119.011136 pubmed: 32060096 pmcid: 7105298
Jocher G et al (2022) ADAM10 and ADAM17 promote SARS-CoV-2 cell entry and spike protein-mediated lung cell fusion. EMBO Rep 23:e54305. https://doi.org/10.15252/embr.202154305
doi: 10.15252/embr.202154305 pubmed: 35527514 pmcid: 9171409
Neitzel H (1986) A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 73:320–326. https://doi.org/10.1007/BF00279094
doi: 10.1007/BF00279094 pubmed: 3017841
Kahveci-Turkoz S et al (2023) A structural model of the iRhom-ADAM17 sheddase complex reveals functional insights into its trafficking and activity. Cell Mol Life Sci 80:135. https://doi.org/10.1007/s00018-023-04783-y
doi: 10.1007/s00018-023-04783-y pubmed: 37119365 pmcid: 10148629
Horiuchi K et al (2007) Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 18:176–188. https://doi.org/10.1091/mbc.e06-01-0014
doi: 10.1091/mbc.e06-01-0014 pubmed: 17079736 pmcid: 1751309
Le Gall SM et al (2010) ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci 123:3913–3922. https://doi.org/10.1242/jcs.069997
doi: 10.1242/jcs.069997 pubmed: 20980382 pmcid: 2972273
Lichtenthaler SF, Lemberg MK, Fluhrer R (2018) Proteolytic ectodomain shedding of membrane proteins in mammals-hardware, concepts, and recent developments. EMBO J 37:e99456. https://doi.org/10.15252/embj.201899456
doi: 10.15252/embj.201899456 pubmed: 29976761 pmcid: 6068445
Qing X et al (2016) iRhom2 regulates CSF1R cell surface expression and non-steady state myelopoiesis in mice. Eur J Immunol 46:2737–2748. https://doi.org/10.1002/eji.201646482
doi: 10.1002/eji.201646482 pubmed: 27601030 pmcid: 5149455
Orme JJ et al (2016) Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE. Clin Immunol 169:58–68. https://doi.org/10.1016/j.clim.2016.05.011
doi: 10.1016/j.clim.2016.05.011 pubmed: 27237127 pmcid: 5193537
Zubarev RA (2013) The challenge of the proteome dynamic range and its implications for in-depth proteomics. Proteomics 13:723–726. https://doi.org/10.1002/pmic.201200451
doi: 10.1002/pmic.201200451 pubmed: 23307342
Schumacher N et al (2023) EGFR stimulation enables IL-6 trans-signalling via iRhom2-dependent ADAM17 activation in mammary epithelial cells. Biochim Biophys Acta Mol Cell Res 1870:119489. https://doi.org/10.1016/j.bbamcr.2023.119489
doi: 10.1016/j.bbamcr.2023.119489 pubmed: 37271223
Vincent B et al (2001) The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J Biol Chem 276:37743–37746. https://doi.org/10.1074/jbc.M105677200
doi: 10.1074/jbc.M105677200 pubmed: 11477090
Malapeira J, Esselens C, Bech-Serra JJ, Canals F, Arribas J (2011) ADAM17 (TACE) regulates TGFbeta signaling through the cleavage of vasorin. Oncogene 30:1912–1922. https://doi.org/10.1038/onc.2010.565
doi: 10.1038/onc.2010.565 pubmed: 21170088
Miller G, Lipman M (1973) Release of infectious epstein-barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A 70:190–194. https://doi.org/10.1073/pnas.70.1.190
doi: 10.1073/pnas.70.1.190 pubmed: 4346033 pmcid: 433213
Kunzel U et al (2018) FRMD8 promotes inflammatory and growth factor signalling by stabilising the iRhom/ADAM17 sheddase complex. Elife 7:e35012. https://doi.org/10.7554/eLife.35012
doi: 10.7554/eLife.35012 pubmed: 29897336 pmcid: 6042961
Oikonomidi I et al (2018) iTAP, a novel iRhom interactor, controls TNF secretion by policing the stability of iRhom/TACE. Elife 7:e35032. https://doi.org/10.7554/eLife.35032
doi: 10.7554/eLife.35032 pubmed: 29897333 pmcid: 6042963
Dusterhoft S et al (2021) The iRhom homology domain is indispensable for ADAM17-mediated TNFalpha and EGF receptor ligand release. Cell Mol Life Sci 78:5015–5040. https://doi.org/10.1007/s00018-021-03845-3
doi: 10.1007/s00018-021-03845-3 pubmed: 33950315 pmcid: 8233286
Hewitt EW (2003) The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology 110:163–169. https://doi.org/10.1046/j.1365-2567.2003.01738.x
doi: 10.1046/j.1365-2567.2003.01738.x pubmed: 14511229 pmcid: 1783040
Blees A et al (2017) Structure of the human MHC-I peptide-loading complex. Nature 551:525–528. https://doi.org/10.1038/nature24627
doi: 10.1038/nature24627 pubmed: 29107940
Ritz U, Seliger B (2001) The transporter associated with antigen processing (TAP): structural integrity, expression, function, and its clinical relevance. Mol Med 7:149–158
doi: 10.1007/BF03401948 pubmed: 11471551 pmcid: 1950029
Barends M et al (2023) Dynamic interactome of the MHC I peptide loading complex in human dendritic cells. Proc Natl Acad Sci U S A 120:e2219790120. https://doi.org/10.1073/pnas.2219790120
doi: 10.1073/pnas.2219790120 pubmed: 37307450 pmcid: 10288655
Zarezadeh Mehrabadi A et al (2022) The roles of interleukin-1 receptor accessory protein in certain inflammatory conditions. Immunology 166:38–46. https://doi.org/10.1111/imm.13462
doi: 10.1111/imm.13462 pubmed: 35231129
Toth AB et al (2013) Synapse maturation by activity-dependent ectodomain shedding of SIRPalpha. Nat Neurosci 16:1417–1425. https://doi.org/10.1038/nn.3516
doi: 10.1038/nn.3516 pubmed: 24036914 pmcid: 3820962
Barclay AN (2009) Signal regulatory protein alpha (SIRPalpha)/CD47 interaction and function. Curr Opin Immunol 21:47–52. https://doi.org/10.1016/j.coi.2009.01.008
doi: 10.1016/j.coi.2009.01.008 pubmed: 19223164 pmcid: 3128989
Lichtenthaler SF, O’Hara BF, Blobel CP (2015) iRhoms in the brain-a new frontier? Cell Cycle 14:3003–3004. https://doi.org/10.1080/15384101.2015.1084187
doi: 10.1080/15384101.2015.1084187 pubmed: 26291882 pmcid: 4825628
Wong GH, Bartlett PF, Clark-Lewis I, Battye F, Schrader JW (1984) Inducible expression of H-2 and Ia antigens on brain cells. Nature 310:688–691. https://doi.org/10.1038/310688a0
doi: 10.1038/310688a0 pubmed: 6433204

Auteurs

Matteo Calligaris (M)

Department of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Proteomics Group of Ri.MED Foundation, via Ernesto Tricomi 5, 90127, Palermo, Italy.
Department of Pharmacy, University of Pisa, via Bonanno 6, 56126, Pisa, Italy.

Donatella P Spanò (DP)

Department of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Proteomics Group of Ri.MED Foundation, via Ernesto Tricomi 5, 90127, Palermo, Italy.
STEBICEF (Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche), Università degli Studi di Palermo, Viale delle Scienze Ed. 16, 90128, Palermo, Italy.

Simone Bonelli (S)

Department of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Proteomics Group of Ri.MED Foundation, via Ernesto Tricomi 5, 90127, Palermo, Italy.
STEBICEF (Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche), Università degli Studi di Palermo, Viale delle Scienze Ed. 16, 90128, Palermo, Italy.

Stephan A Müller (SA)

German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen Strasse 17, 81377, Munich, Germany.
Neuroproteomics, School of Medicine, Klinikum rechts der Isar, Technische Universität München, 81675, Munich, Germany.

Claudia Carcione (C)

Department of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Ri.MED Foundation, via Ernesto Tricomi 5, 90127, Palermo, Italy.

Danilo D'apolito (D)

Department of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Ri.MED Foundation, via Ernesto Tricomi 5, 90127, Palermo, Italy.

Giandomenico Amico (G)

Department of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Ri.MED Foundation, via Ernesto Tricomi 5, 90127, Palermo, Italy.

Monica Miele (M)

Department of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Ri.MED Foundation, via Ernesto Tricomi 5, 90127, Palermo, Italy.

Mariangela Di Bella (M)

Department of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Ri.MED Foundation, via Ernesto Tricomi 5, 90127, Palermo, Italy.

Giovanni Zito (G)

Department of Research, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), 90127, Palermo, Italy.

Elisa Nuti (E)

Department of Pharmacy, University of Pisa, via Bonanno 6, 56126, Pisa, Italy.

Armando Rossello (A)

Department of Pharmacy, University of Pisa, via Bonanno 6, 56126, Pisa, Italy.

Carl P Blobel (CP)

Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, Program in Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, New York, NY, USA.
Institute for Advanced Study, Technical University Munich, Munich, Germany.

Stefan F Lichtenthaler (SF)

German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen Strasse 17, 81377, Munich, Germany.
Neuroproteomics, School of Medicine, Klinikum rechts der Isar, Technische Universität München, 81675, Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Simone D Scilabra (SD)

Department of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Proteomics Group of Ri.MED Foundation, via Ernesto Tricomi 5, 90127, Palermo, Italy. sdscilabra@fondazionerimed.com.

Classifications MeSH